Depressione
RECOVER trial suggests vagus nerve stimulation benefits some patients with severe treatment-resistant depression for at least two years
Riportato dall'IA Immagine generata dall'IA Verificato
An implanted device that stimulates the vagus nerve was associated with sustained improvements in symptoms, functioning and quality of life among adults with long-standing, treatment-resistant major depression, according to researchers reporting two-year follow-up data from the ongoing RECOVER study led by Washington University School of Medicine in St. Louis.
Researchers at the University of Victoria have discovered that the protein Reelin could help repair leaky gut caused by chronic stress and alleviate depression symptoms. A single injection restored Reelin levels in preclinical models, showing antidepressant effects. The findings highlight the gut-brain connection in mental health.
Riportato dall'IA
Una meta-analisi internazionale su quasi 24.000 anziani rivela che il supporto emotivo riduce i sintomi depressivi in vecchiaia più dell'aiuto pratico quotidiano. La ricerca, pubblicata sull'American Journal of Epidemiology, ha analizzato dati di 11 studi condotti in vari paesi, tra cui il Brasile. Gli esperti sottolineano l'importanza dei legami affettivi per la salute mentale degli anziani.
Neuroscientists from Columbia University and McGill University have discovered that high levels of the stress-related protein SGK1 are associated with depression and suicidal behavior in people who experienced childhood adversity. This finding suggests potential for new antidepressants targeting SGK1, particularly for those resistant to current treatments. The research highlights how early trauma alters brain chemistry differently from other forms of depression.
Riportato dall'IA
Researchers at McGill University and the Douglas Institute have pinpointed two types of brain cells altered in people with depression. Using advanced genomic analysis on post-mortem brain tissue, they found genetic disruptions in excitatory neurons and microglia. The findings, published in Nature Genetics, could lead to more targeted treatments for the condition affecting over 264 million people worldwide.